A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture (CAST)
Primary Purpose
Emergency Service, Hospital, Child/Adolescent Problem, Acute Pain
Status
Withdrawn
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
INF2.0 + IBU
INF1.0 + IBU
Sponsored by
About this trial
This is an interventional treatment trial for Emergency Service, Hospital focused on measuring Children, Musculoskeletal injury, Emergency department, Analgesia, Opioids
Eligibility Criteria
Inclusion Criteria:
- pain score >49 mm on the VAS at triage
- between the ages of 8 and 17 years
- presenting to the ED with a suspected fracture of the upper of lower limb
- who can communicate in either French or English
Exclusion Criteria:
- known allergy to fentanyl, hydromorphone, ibuprofen, or artificial colouring
- triage nurse suspicion of child abuse
- inability to self-report pain
- chronic pain that necessitates daily analgesic use
- NSAID or opioid use within the three hours prior to ED presentation
- trauma to >1 limb
- known hepatic or renal disease/dysfunction
- known bleeding disorder
- neuro-cognitive disability that precludes assent and/or participating in the study
- known history of obstructive sleep apnea
- a suspected fracture of the nose
- significant head injury, as determined by the clinical team/triage nurse.
Sites / Locations
- Stollery Children's Hospital
- Children's Hospital London Health Sciences Centre
- CHU Sainte-Justine Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
INF2.0 + IBU
INF1.0 + IBU
Arm Description
The participant will receive a dose of intranasal fentanyl (2.0 mcg/kg) AND a dose of oral ibuprofen (10 mg/kg).
The participant will receive a dose of intranasal (1.0 mcg/kg) AND a dose of oral ibuprofen (10 mg/kg).
Outcomes
Primary Outcome Measures
Mean difference in pain scores between groups
Measure: Visual Analogue Scale (VAS)
Secondary Outcome Measures
Mean difference in pain scores between groups
Measure: Visual Analogue Scale (VAS)
Proportion of children administered a rescue analgesic
Measure: Clinical data (yes/no)
Proportion of children with adverse events in each group
At each assessment points, the research nurse will record the occurence of adverse events (clinical data)
Proportion of children with an RSS score > 3 in each group
At each assessment points, the research nurse will evaluate the child's sedation level using the Ramsay Sedation Scale (RSS)
Satisfaction of children and parents regarding pain management
Dichotomized question (yes/no)
Proportion of children with serious adverse events (SAE) in each group
The research nurse will record the occurence of serious adverse events (clinical data)
Full Information
NCT ID
NCT02985177
First Posted
October 25, 2016
Last Updated
November 22, 2022
Sponsor
St. Justine's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02985177
Brief Title
A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture
Acronym
CAST
Official Title
A Randomized Controlled Trial of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture at Triage (CAST Trial)
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Withdrawn
Why Stopped
We couldn't obtain funds for this study
Study Start Date
January 2020 (Anticipated)
Primary Completion Date
July 2021 (Anticipated)
Study Completion Date
September 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
St. Justine's Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
MSK-I is the most common cause for ED visits for children with pain, with a child's risk of sustaining a fracture ranging from 27-42% by the age of 16 years. MSK-I is known to generate moderate to severe pain in most children and the ED serves as the critical entry point for these injured children. This study aims to provide rapid and sustained pain management for children presenting with a MSK-I in the ED. The investigators will compare the efficacy of two possible medication combinations of fentanyl intranasal (1.0 mcg/kg) + oral ibuprofen (10 mg/kg) and fentanyl intranasal (2.0 mcg/kg) + oral ibuprofen (10 mg/kg) for the rapid, adequate and sustained pain management of children with suspected fracture.
The investigators believe that the combination of different dosage of intranasal fentanyl with ibuprofen will lead to better pain treatment by providing a consistent and adequate level of analgesia throughout the entire ED visit, including prior to physician exam and during painful radiologic procedures.
Detailed Description
Pain management for children with a suspected fracture is suboptimal in the Emergency Department (ED). This type of musculoskeletal injury (MSK-I) often generates moderate to severe pain (> 49 mm on 0 to 100 mm Visual Analogue Scale (VAS)), and requires rapid and sustained pain management for the duration of the physical examination, diagnostic imaging (X-Ray), immobilization and occasionally fracture reduction. Current standard care includes the use of oral ibuprofen (IBU), a non-steroidal anti-inflammatory drug (NSAID), for mild-to-moderate MSK-I pain in the ED. However, ibuprofen has been shown to be inadequate for moderate-to-severe pain when used alone. A number of small/single centre studies suggest that intranasal fentanyl (INF) is effective for rapidly decreasing MSK-I related pain in children with a quick onset of 10 minutes and a peak action of 20 minutes. However, the duration of its analgesic effect is limited to a maximum of 60 minutes, which does not provide an optimal pain management for the duration of the ED stay, which typically lasts up to three hours. Typically, patients with a fracture have sustained pain throughout their ED stay due to imaging, splinting and repeated physical exams. Our objective is to examine the efficacy of a combination of intranasal and oral analgesics for pain management in children presenting to the ED with a suspected fracture. Our primary research question: For children presenting to the ED with a suspected fracture, is a combination of INF1.0 (1.0 mcg/kg, maximum dose of 100 mcg) and IBU (10 mg/kg, maximum dose of 600 mg) more efficacious than a combination of INF2.0 (2.0 mcg/kg, maximum dose of 100 mcg) and oral ibuprofen (10 mg/kg, maximum dose of 600 mg) to decrease pain at 15 minutes post-administration? Our primary hypothesis is: A combination of INF2.0 and IBU will be more efficacious than a combination of INF1.0 and IBU to decrease pain at 15 minutes post-administration.
Methods. Design: This study is a single-blind, two-arm, three-centre RCT of a combination of analgesics for pain management of children presenting to the ED with a suspected fracture will be performed. Settings: Children will be recruited in the following EDs: CHU Sainte-Justine (Montreal, QC), Stollery Children's Hospital (Edmonton, AB), and Children's Hospital of the London Health Sciences Centre (London, ON). Sample. Inclusion criteria: Will be include children: (a) with a pain score >49 mm on VAS at triage, (b) between the ages of 7 and 17 years, (c) presenting to the ED with a suspected fracture of the upper or lower limb, and (d) who can communicate in either French or English. Exclusion criteria: Will be exclude children with (a) known allergy to fentanyl or ibuprofen, (b) triage nurse suspicion of child abuse, (c) inability to self-report pain, (d) chronic pain that necessitates daily analgesic use, (e) NSAID or opioid analgesic use within the three hours prior to ED presentation, (f) trauma to >1 limb, (g) known hepatic or renal disease/dysfunction, (h) known bleeding disorder, (i) neuro-cognitive disability that precludes assent and/or participating in the study, (j) known history of obstructive sleep apnea (k) a suspected fracture of the nose, or (l) significant head injury, as determined by the clinical team/triage nurse.
Allocation and Randomization: A biostatistician, independent to our study team, will generate the randomization scheme that will consist of a computer-generated random listing of the treatment using a 1:1 allocation scheme. Randomization will be stratified by center using block-randomization (with permuted block sizes). Enrolled children will be allocated to (a) INF 1.0 mcg/kg (up to a maximum of 100 mcg) via intranasal atomization + oral IBU 10 mg/kg (up to a maximum of 600 mg) OR (b) INF 2.0 mcg/kg (up to a maximum of 100 mcg) via intranasal atomization + oral IBU 10 mg/kg (up to a maximum of 600 mg.
Sample Size: Accounting for a 10% attrition rate, we determined that enrollment of 172 participants would provide at least 90 % power to detect a 10 mm absolute difference in mean pain scores between groups at 15 minutes post-medication administration (T-15), at an alpha level of 5 %.
Primary efficacy outcome: Mean difference in pain scores between groups at 15 minutes post-medication administration (T-15) using the Visual Analogue Scale (VAS). Secondary outcomes: (a) Mean differences in pain scores between groups at 30 min (T-30), 60 min (T-60), 90 min (T-90), 120 min (T-120) after medication administration, during the medical examination (T-ME), and during radiographic procedure (T-XR), (b) the proportion of children administered a rescue analgesic in the 60 minutes following administration of study medication, (c) the proportion of children with adverse events at T-15, T-30, T-60, T-90, T-120, T-ME and T-XR, (d) the proportion of children with serious adverse events at T-15, T-30, T-60, T-90, T-120, T-ME and T-XR, (e) the proportion of children in each group with an RSS score > 3 (f) satisfaction of children and parents regarding pain management (T-120).
Relevance: In response to the persistent problem of inadequate and delayed analgesia, the investigators believe that a combination of rapidly acting (INF) and longer-acting (oral ibuprofen) medications will address both the delay in the time to effective analgesia and overall under-treatment of suspected fracture pain. The team anticipate that an RCT demonstrating the efficacy of a combination of fast and long-acting analgesics will significantly improve the treatment for children with a suspected fracture in the ED. The investigators hypothesize that use of INF2.0 and oral IBU will provide rapid pain relief that is sustained for the duration of the ED visit. Promotion of adequate acute pain treatment of children presenting to the ED will prevent the known short and long-term effects of inadequately treated pain in children previously demonstrated by our team, including unpleasant memories, stress and anxiety upon future visits to healthcare and compromised functional outcomes such as missed school.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Emergency Service, Hospital, Child/Adolescent Problem, Acute Pain, Fentanyl, Ibuprofen, Analgesics, Opioid, Anti-inflammatory Agents, Non-steroidal
Keywords
Children, Musculoskeletal injury, Emergency department, Analgesia, Opioids
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
INF2.0 + IBU
Arm Type
Experimental
Arm Description
The participant will receive a dose of intranasal fentanyl (2.0 mcg/kg) AND a dose of oral ibuprofen (10 mg/kg).
Arm Title
INF1.0 + IBU
Arm Type
Active Comparator
Arm Description
The participant will receive a dose of intranasal (1.0 mcg/kg) AND a dose of oral ibuprofen (10 mg/kg).
Intervention Type
Drug
Intervention Name(s)
INF2.0 + IBU
Intervention Description
Analgesics
Intervention Type
Drug
Intervention Name(s)
INF1.0 + IBU
Intervention Description
Analgesics
Primary Outcome Measure Information:
Title
Mean difference in pain scores between groups
Description
Measure: Visual Analogue Scale (VAS)
Time Frame
15 minutes post-medication administration (T-15)
Secondary Outcome Measure Information:
Title
Mean difference in pain scores between groups
Description
Measure: Visual Analogue Scale (VAS)
Time Frame
30 min (T-30), 60 min (T-60), 90 min (T-90), 120 min (T-120) post-medication administration, during the medical examination (T-ME), and during radiographic procedure (T-XR)
Title
Proportion of children administered a rescue analgesic
Description
Measure: Clinical data (yes/no)
Time Frame
Within 60 minutes following administration of study medication
Title
Proportion of children with adverse events in each group
Description
At each assessment points, the research nurse will record the occurence of adverse events (clinical data)
Time Frame
15 min (T-15), 30 min (T-30), 60 min (T-60), 90 min (T-90), 120 min (T-120) after medication administration, during the medical examination (T-ME), and during radiographic procedure (T-XR), 24 hours post-discharge from the ED
Title
Proportion of children with an RSS score > 3 in each group
Description
At each assessment points, the research nurse will evaluate the child's sedation level using the Ramsay Sedation Scale (RSS)
Time Frame
15 min (T-15), 30 min (T-30), 60 min (T-60), 90 min (T-90), 120 min (T-120) after medication administration, during the medical examination (T-ME), and during radiographic procedure (T-XR)
Title
Satisfaction of children and parents regarding pain management
Description
Dichotomized question (yes/no)
Time Frame
120 min (T-120) after medication administration
Title
Proportion of children with serious adverse events (SAE) in each group
Description
The research nurse will record the occurence of serious adverse events (clinical data)
Time Frame
After medication administration until discharge
10. Eligibility
Sex
All
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
pain score >49 mm on the VAS at triage
between the ages of 7 and 17 years
presenting to the ED with a suspected fracture of the upper of lower limb
who can communicate in either French or English
Exclusion Criteria:
known allergy to fentanyl, ibuprofen
triage nurse suspicion of child abuse
inability to self-report pain
chronic pain that necessitates daily analgesic use
NSAID or opioid use within the three hours prior to ED presentation
trauma to >1 limb
known hepatic or renal disease/dysfunction
known bleeding disorder
neuro-cognitive disability that precludes assent and/or participating in the study
known history of obstructive sleep apnea
a suspected fracture of the nose
significant head injury, as determined by the clinical team/triage nurse.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Le May Sylvie, PhD
Organizational Affiliation
St. Justine's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stollery Children's Hospital
City
Edmonton
State/Province
Alberta
Country
Canada
Facility Name
Children's Hospital London Health Sciences Centre
City
London
State/Province
Ontario
Country
Canada
Facility Name
CHU Sainte-Justine Hospital
City
Montréal
State/Province
Quebec
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture
We'll reach out to this number within 24 hrs